Contains Solid Synthetic Resin Patents (Class 424/501)
-
Publication number: 20140050799Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: ApplicationFiled: April 10, 2012Publication date: February 20, 2014Applicant: SHANDONG LUYE PHARMACEUTICAL CO., LTD.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 8653320Abstract: The invention relates generally to an odor-absorbing superabsorbing composition, a process for production of an odor-absorbing superabsorbing composition, a composite comprising an odor-absorbing superabsorbing composition, a hygiene article comprising a composite, chemical products comprising or based on an odor-absorbing superabsorbing composition or a composite, as well as the use of an odor-absorbing superabsorbing composition or of a composite in chemical products.Type: GrantFiled: November 17, 2006Date of Patent: February 18, 2014Assignee: Evonik Degussa GmbHInventors: Franck Furno, Felix Müller, Jörg Peggau, Michael Keup, Harald Schmidt
-
Patent number: 8652528Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.Type: GrantFiled: April 12, 2013Date of Patent: February 18, 2014Assignee: BIND Therapeutics, Inc.Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
-
Patent number: 8647742Abstract: The invention relates to a diagnostic gel composition for use as a diagnostic element in diagnostic devices. The diagnostic gel composition is derived from a compound having a formula D-Sp-Po wherein D is a diagnostic group; Sp is a hydrophilic spacer group; and Po is a polymerizable group. The diagnostic gel composition of the invention has dimensions ranging from about 250 nanometers to about 1000 micrometers, and a Young's modulus ranging from about 10 kilopascals to about 200 kilopascals. The invention also provides method for making the diagnostic gel composition. The method comprises providing a composition comprising a porogen, an initiator and a compound having a formula D-Sp-Po; polymerizing the composition to form a polymerized composition; and washing the polymerized composition to form the diagnostic gel composition.Type: GrantFiled: December 28, 2009Date of Patent: February 11, 2014Assignee: Achira Labs Pvt. Ltd.Inventors: Dhananjaya Dendukuri, Reeta Katiyar, Lakshmi P. Sivakumaran
-
Publication number: 20140037749Abstract: The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are used in the treatment of diseases (e.g., type 1 diabetes), and related methods (e.g., diagnostic methods, research methods, drug screening).Type: ApplicationFiled: March 14, 2013Publication date: February 6, 2014Applicant: NORTHWESTERN UNIVERSITYInventor: NORTHWESTERN UNIVERSITY
-
Patent number: 8642089Abstract: The invention relates to a method for producing active ingredient-containing granules or powders involving the following steps: a) melting a mixture consisting of a pharmaceutical active ingredient and of a (meth)acrylate copolymer, which is comprised of 40 to 75 wt. % of radically polymerized C1 to C4 alkyl esters of acrylic acid or of methacrylic acid and can be comprised of 25 to 60 wt. % (meth)acrylate monomers having an anionic group in the alkyl radial; b) extruding the mixture, and; c) comminuting the extrudate to form a granule or powder. The inventive method is characterized in that the active ingredient is the salt of an alkaline substance, and in that the pH value, which can be measured on the obtained powder or granule, is equal to or less than pH 7.0. The invention also relates to pharmaceutical dosage forms or precursors thereof, which can be produced using the inventive method.Type: GrantFiled: January 30, 2003Date of Patent: February 4, 2014Assignee: Evonik Roehm GmbHInventors: Hans-Ulrich Petereit, Christian Meier, Andreas Gryczke
-
Publication number: 20140030351Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.Type: ApplicationFiled: September 27, 2013Publication date: January 30, 2014Applicant: BIND Therapeutics, Inc.Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Publication number: 20140030350Abstract: The present invention relates to microparticles comprising a gel body, wherein the gel body comprises a synthetic polymer and a drug, wherein the microparticles have an average diameter in the range 40 to 1500 ?m, wherein the polymer is cross-linked by groups comprising disulfide linkages and is in the form of a hydrogel.Type: ApplicationFiled: January 27, 2012Publication date: January 30, 2014Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Koorosh Ashrafi, Andrew Lennard Lewis, Clare Heaysman, Andrew Lloyd, Gary Philips
-
Publication number: 20140030352Abstract: The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ajay Jaysingh KHOPADE, Subhas Balaram BHOWMICK, Natarajan ARULSUDAR
-
Patent number: 8632820Abstract: Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.Type: GrantFiled: September 24, 2011Date of Patent: January 21, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventors: Wouter E. Roorda, Stephen D. Pacetti
-
Publication number: 20140017330Abstract: The present invention provides nanogel formulations and methods of use thereof.Type: ApplicationFiled: April 4, 2012Publication date: January 16, 2014Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventor: Serguei V. Vinogradov
-
Patent number: 8623414Abstract: A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of macromolecular assemblies.Type: GrantFiled: May 31, 2006Date of Patent: January 7, 2014Assignee: Malvren Cosmeceutics LimitedInventor: Stephen Tonge
-
Patent number: 8617614Abstract: The present invention provides a microsphere with a slow-release period from about two weeks to about four weeks following administration, to enable a higher content of a drug to be included, to suppress an initial burst of the drug, and to maintain an optimal, effective blood concentration during the slow-release period. In a microsphere containing a drug and polylactic acid/glycolic acid (PLGA) copolymer, the amount of PLGA copolymer per part by weight of the drug is from about 3 to about 10 parts by weight; the average particle size of the microsphere is from about 20 to about 50 ?m; and (3) the PLGA copolymer has a weight-average molecular weight from about 10,000 to about 50,000 and a PLGA compositional ratio from about 75/25 to about 50/50. The microsphere promotes the production of various endogenous repair factors useful against various tissue disorders.Type: GrantFiled: October 18, 2007Date of Patent: December 31, 2013Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sakai, Takahiro Uchida
-
Publication number: 20130344160Abstract: The present invention relates to a macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I) (CH2?CR1)CO—K wherein: —K represents O-Z or NH-Z, Z representing (CR2R3)m—CH3, (CH2—CH2—O)m—H, (CH2—CH2—O)m—CH3, (CH2)m—NR4R5 with m representing an integer from 1 to 30; —R1, R2, R3, R4 and R5 independently represent H or a C1-C6 alkyl; and (ii) at least one bio-resorbable block copolymer cross-linker, and wherein the macromolecule is chosen in the group consisting of proteins and nucleic acids.Type: ApplicationFiled: March 9, 2012Publication date: December 26, 2013Applicants: OCCLUGEL, UNIVERSITE PARIS DIDEROT - PARIS 7, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Laurence Moine, Alexandre Laurent, Michel Wassef, Laurent Bedouet, Stephanie Louguet, Valentin Verret, Emeline Servais
-
Publication number: 20130344158Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.Type: ApplicationFiled: June 5, 2013Publication date: December 26, 2013Applicant: BIND Therapeutics, Inc.Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Publication number: 20130344159Abstract: The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH2?CR1)CO—K (1) wherein: K represents O—Z or NH—Z, Z representing (CR2R3)m-CH3, (CH2—CH2—O)m-H, (CH2—CH2—O)m-CH3, (CH2)m-NR4R5 with m representing an integer from 1 to 30; R1, R2, R3, R4 and R5 independently represent H or a C1-C6 alkyl; (ii) at least between 0.1 and 50% mol, advantageously between 1 and 30% mol, more advantageously between 1 and 20 mol % of a cyclic monomer having a exomethylene group of formula (II) wherein: R6, R7, R8 and R9 represent independently H or a C5-C7 aryl group or R6 and R9 are absent and R7 and R8 form together with the carbon atom on which they are bonded a C5-C7 aryl group; i and j represent independently an integer chosen between 0 and 2; X represents either O or X is not present and in this latter case, CR6R7 and CR8R9 are linked via a single bond C—C and (iii) at least one bio-resorbable block copolymer cross-linker.Type: ApplicationFiled: March 9, 2012Publication date: December 26, 2013Applicants: OCCLUGEL, UNIVERSITE PARIS DIDEROT - PARIS 7, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Laurence Moine, Alexandre Laurent, Michel Wassef, Laurent Bedouet, Stephanie Louguet, Valentin Verret, Emeline Servais
-
Publication number: 20130337078Abstract: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.Type: ApplicationFiled: August 16, 2013Publication date: December 19, 2013Applicants: THE TRUSTEES OF PRINCETON UNIVERSITY, CELATOR PHARMACEUTICALS, INC.Inventors: Lawrence D. MAYER, Robert K. PRUD'HOMME, Christine J. ALLEN, Walid S. SAAD
-
Publication number: 20130337077Abstract: Provided is a nanosphere for delivery of a therapeutic agent comprising: a polymer matrix; discrete liquid oil droplets dispersed in the polymer matrix; and a therapeutic agent dissolved or dispersed in the oil. In some embodiments, the nanosphere is pegylated. In some embodiments, the nanosphere has a diameter of from about 100 nm to about 300 nm. In further preferred embodiments, the nanosphere has a diameter of from about 150 nm to about 250 nm. In yet further embodiments, the nanosphere has a diameter of from about 180 nm to about 220 nm. In some embodiments, the oil comprises a lipid or a phospholipid. In further embodiments, the lipid or the phospholipid has a melting point below 20° C. In some embodiments, the polymer is a natural, modified or synthetic polymer. In further embodiments, the polymer is biodegradable.Type: ApplicationFiled: June 14, 2013Publication date: December 19, 2013Inventors: Ho Lun Wong, Mayuri Narvekar, Hui Yi Xue
-
Publication number: 20130337025Abstract: The invention relates to a method for the production of biosourced aliphatic polyester powder having a volume median diameter of less than 30 ?m, comprising: a step consisting in supplying an aliphatic polyester having an inherent viscosity of less than 0.5 dl/g; and a step consisting in grinding the polyester, so as to obtain a polyester powder having a volume median diameter of less than 30 ?m. The invention also relates to a powder in which the particles have a volume median diameter of less than 30 ?m and are impregnated with a compound selected from among polyols and/or carboxylic acids. The invention further relates to the use of the powder for the production of cosmetic, pharmaceutical and perfume products.Type: ApplicationFiled: January 20, 2012Publication date: December 19, 2013Applicant: ARKEMA FRANCEInventors: Guillaume Le, Cyrille Mathieu, Karine Loyen, Jean Laurent Pradel, Jean Jacques Flat
-
Patent number: 8609142Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.Type: GrantFiled: December 13, 2012Date of Patent: December 17, 2013Assignee: BIND Therapeutics, Inc.Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
-
Patent number: 8603539Abstract: Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent.Type: GrantFiled: October 17, 2011Date of Patent: December 10, 2013Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Arutla Srinivas, Harshal P. Bhagwatwar, Vakati Venkat Arvind, Saravana Perumal, Vemula Sathya Narayana, Mandavalli Srirama Sarveswara Rao, Venkateswarlu Vobalaboina, Nookaraju Venkata Sreedharala
-
Publication number: 20130323317Abstract: The present invention relates to injectable compositions comprising biocompatible, swellable, hydrophilic, non-toxic and substantially spherical microspheres useful for tissue bulking. The invention also relates to methods of tissue bulking, particularly for the treatment of Gastro-esophageal reflux disease, urinary incontinence, or urinary reflux disease, using the injectable compositions.Type: ApplicationFiled: August 8, 2013Publication date: December 5, 2013Applicant: Biosphere Medical, Inc.Inventors: Jean-Marie Vogel, Richard Thomas, Egisto Boschetti
-
Publication number: 20130323319Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.Type: ApplicationFiled: November 14, 2011Publication date: December 5, 2013Applicant: GETTS CONSULTING AND PROJECT MANAGEMENTInventors: Daniel R. Getts, Rachael Terry, Nicholas King
-
Publication number: 20130323177Abstract: A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating nanoparticle according to the present disclosure is accumulated in the tumor tissue in large quantity and generates strong ultrasound wave signals, it can be usefully used as a contrast agent for ultrasonic imaging.Type: ApplicationFiled: May 31, 2013Publication date: December 5, 2013Inventors: Ick Chan Kwon, Kwang Meyung Kim, Kuiwon Choi, Heebeom Koo, Hyun Su Min, Inchan Youn
-
Publication number: 20130323316Abstract: The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.Type: ApplicationFiled: August 7, 2013Publication date: December 5, 2013Applicant: Biosphere Medical, Inc.Inventors: Jean-Marie Vogel, Richard Thomas, Egisto Boschetti
-
Patent number: 8597679Abstract: Use of crosslinked polyvinylpyrrolidone with an average particle size of 5-60 ?m and a hydration capacity of greater than 7 g/g as tablet disintegrant.Type: GrantFiled: December 11, 2006Date of Patent: December 3, 2013Assignee: BASF SEInventors: Karl Kolter, Bernhard Fussnegger, Michael Kerber, Harald Armbruster, Hubertus Folttmann, Ralf Widmaier, Marianna Pierobon
-
Publication number: 20130316010Abstract: A pharmaceutical composition is provided comprising microparticles encapsulating high weight percent active agent and providing sustained release over a prolonged period of time of active agent levels bioequivalent to direct administration of active agent. Polymeric microparticle compositions containing one or more active agents, and methods of making and using thereof, are described. The microparticles are optimized for the agent to be delivered, so that the hydrophobicity or hydrophilicity of the polymer and charge of the polymer maximizes loading of the agent, and the selection and molecular weight of the polymers maximize release of an effective amount of the active agent for the desired period of time.Type: ApplicationFiled: October 18, 2011Publication date: November 28, 2013Applicant: Case Western Reserve UniversityInventor: Erin Lavik
-
Publication number: 20130309314Abstract: The disclosure provides a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof.Type: ApplicationFiled: November 25, 2011Publication date: November 21, 2013Inventors: Youxin Li, Aiping Wang, Wanhui Liu, Kaoxiang Sun, Jun Li, Lifang Sun
-
Patent number: 8586098Abstract: A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen.Type: GrantFiled: June 15, 2011Date of Patent: November 19, 2013Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Yiqing Tang, Maria Victoria Gonzalez Fajardo
-
Publication number: 20130302431Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.Type: ApplicationFiled: March 13, 2013Publication date: November 14, 2013Inventors: R. Loch Macdonald, Cara R. Davis, Kevin Burton, Gary Winchester, Angela R. Stella
-
Publication number: 20130302432Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.Type: ApplicationFiled: May 28, 2013Publication date: November 14, 2013Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Publication number: 20130302433Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.Type: ApplicationFiled: June 11, 2013Publication date: November 14, 2013Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
-
Patent number: 8580311Abstract: Methods for the preparation of polymer-templated core-shell nanoparticles include the steps of (a) preparing a cationic polymeric core material comprising polymeric micelles, and (b) coating the core material with a silica-comprising shell by depositing the shell onto the polymeric micelles from at least one silica precursor to form the core-shell nanoparticles. Compositions which include the core-shell nanoparticles are adapted to facilitate controlled delivery of at least one active agent into a system in response to controlled changes in the pH of the system.Type: GrantFiled: January 31, 2012Date of Patent: November 12, 2013Assignee: DSM IP Assets B.V.Inventors: Steven Armes, Jian-Jun Yuan
-
Publication number: 20130295191Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.Type: ApplicationFiled: June 4, 2013Publication date: November 7, 2013Inventors: Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
-
Patent number: 8574629Abstract: An injectable hydrogel includes a hydrogel matrix based on (a) single-phase-type cross-linked biopolymer(s), characterized in that previously cross-linked biopolymer hydrogel particles are co-cross-linked with the matrix. A method of and a process for production of the above-mentioned hydrogel are also disclosed.Type: GrantFiled: July 30, 2009Date of Patent: November 5, 2013Assignee: Anteis S.A.Inventor: Samuel Gavard Molliard
-
Patent number: 8574631Abstract: Water-dispersible particles are provided that disperse into more than 100 pieces upon contact with water. Particles include from 5% to 99.9% of a nitrogen-containing ingredient bioavailable to a targeted desirable organism and 1% to 95% of a bentonite binder component. Additionally provided is a process for making a water-dispersible particle, the process including the steps of mechanically aggregating particle components into a pellet. Particle components include a bioavailable nitrogen-containing ingredient and a binder, the components being such that a product particle is dispersed into more than 100 pieces upon contact with water. In a further step of a process for making a water-dispersible particle, the pellet is dried to form a particle. Following administration of a described particle, water is allowed to contact the particle, dispersing it into pieces and thereby delivering a nutrient.Type: GrantFiled: January 6, 2006Date of Patent: November 5, 2013Assignee: The Andersons, Inc.Inventors: Charles W. Anderson, Kenneth Tornberg, Timothy D. Birthisel, James R. Lynch
-
Publication number: 20130287857Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.Type: ApplicationFiled: March 15, 2013Publication date: October 31, 2013Inventors: Ulrich H. von Andrian, Omid C. Farokhzad, Robert S. Langer, Tobias Junt, Elliott Ashley Moseman, Liangfang Zhang, Pamela Basto, Matteo Iannacone, Frank Alexis
-
Patent number: 8568782Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.Type: GrantFiled: March 6, 2006Date of Patent: October 29, 2013Assignee: Alfa Wassermann S.p.A.Inventors: Giuseppe Claudio Viscomi, Ernesto Palazzini, Villiam Zamboni, Maria Rosaria Pantaleo
-
Patent number: 8568788Abstract: The present invention relates to a nanoparticulated anaesthetic composition for topical use in which at least one local anaesthetic agent is encapsulated in polymeric nanoparticles. The present invention also relates to the use of such polymeric nanoparticles comprising at least one local anaesthetic agent in the preparation of an anaesthetic composition for topical application to the skin or mucosa.Type: GrantFiled: March 12, 2008Date of Patent: October 29, 2013Assignees: Biolab Sanus Farmaceutica Ltda, Universidade Federal Do Rio Grande Do SulInventors: Dante Alário Junior, Silvia Stanisçuski Guterres, Adriana Raffin Pohlmann, Lali Rosoni Zancan
-
Publication number: 20130280339Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic)acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.Type: ApplicationFiled: May 28, 2013Publication date: October 24, 2013Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Publication number: 20130280338Abstract: A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.Type: ApplicationFiled: April 17, 2013Publication date: October 24, 2013Inventors: Klaus WENING, Lutz BARNSCHEID, Sebastian SCHWIER
-
Patent number: 8546306Abstract: The invention relates to an aqueous dispersion comprising microcapsules, the capsule wall of which is formed from radically polymerized monomers and the capsule core of which comprises at least one oil, in which the capsule core comprises at least one lipophilic surfactant and the continuous phase of the dispersion comprises at least one agrochemical. In addition, the invention relates to a process for the preparation of an aqueous dispersion by (i) providing an aqueous dispersion comprising microcapsules, the capsule wall of which is formed from radically polymerized monomers and the capsule core of which comprises at least one oil and at least one lipophilic surfactant (microcapsule crude dispersion), and (ii) mixing with at least one agrochemical.Type: GrantFiled: February 4, 2009Date of Patent: October 1, 2013Assignee: BASF SEInventors: Tatjana Levy, Marc Rudolf Jung, Rainer Berghaus, Hans-Peter Hentze, Tobias Joachim Koplin, Jurith Montag, Anke Reinold, Christian Sowa
-
Publication number: 20130251816Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.Type: ApplicationFiled: May 10, 2013Publication date: September 26, 2013Applicant: Bind Therapeutics, Inc.Inventors: Stephen E. Zale, Mir Mukkaram Ali
-
Publication number: 20130251817Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.Type: ApplicationFiled: May 10, 2013Publication date: September 26, 2013Applicant: Bind Therapeutics, Inc.Inventors: Stephen E. Zale, Mir Mukkaram Ali
-
Patent number: 8535727Abstract: A biodegradable delivery system for actives such as pharmaceutical drugs. The delivery system includes actives infused into the capsid of a purified plant virus. The loaded capsids are embedding in electrospun biodegradable polymer fibers, forming a nonwoven fabric.Type: GrantFiled: February 25, 2010Date of Patent: September 17, 2013Assignee: North Carolina State UniversityInventors: Behnam Pourdeyhimi, Steve A. Lommel, Sara Honarbakhsh, Ruben Carbonell, Richard H. Guenther
-
Patent number: 8535644Abstract: Techniques are provided to produce and use non-spherical colloidal particles with independently tuned size, shape, flexibility, and chemical properties. A pre-polymer mixture for forming hydrogel particles includes a percentage of PEGDA selected to impart a target stiffness to the particles and includes, a percentage of acrylic acid selected to impart an independent target chemical function to the particles. The mixture also includes a percentage of photo-initiator to polymerize PEGDA upon exposure to a light source to impart an independently selected target size or shape or both to the particles.Type: GrantFiled: October 13, 2009Date of Patent: September 17, 2013Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Ramin Haghgooie, Patrick Seamus Doyle, Mehmet Toner, Daniel Colin Pregibon
-
Patent number: 8518963Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.Type: GrantFiled: February 13, 2012Date of Patent: August 27, 2013Assignee: BIND Therapeutics, Inc.Inventors: Mir Mukkaram Ali, Abhimanyu Sabnis, David Dewitt, Greg Troiano, James Wright, Maria Figueiredo, Michael Figa, Christina Van Geen Hoven, Young-Ho Song, Jason Auer, Tarikh Christopher Campbell
-
Patent number: 8518451Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: GrantFiled: November 25, 2009Date of Patent: August 27, 2013Assignees: Albany College of Pharmacy and Health Services, Orway Research Institute, Inc.Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
-
Patent number: 8518450Abstract: The invention provides a process for the production of nanoparticle carriers for drug delivery, said nanoparticles being produced by preparing a double emulsion of water-oil-water including one or more polymer which forms the basis of the nanoparticle carrier, blending the drug to be delivered into one of the emulsion phases, doping either the oil-phase or the outer-water phase with a carbohydrate, and spray drying the emulsion to form nanoparticles of a narrow particle size distribution of 100 nm to 1000 nm, which nanoparticles are substantially spherical.Type: GrantFiled: August 17, 2010Date of Patent: August 27, 2013Assignee: CSIRInventor: Lonji Kalombo
-
Methods of formulating and designing liquid drug suspensions containing ion exchange resin particles
Patent number: 8512759Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.Type: GrantFiled: June 7, 2012Date of Patent: August 20, 2013Assignee: Neos Therapeutics, LPInventors: Russell McMahen, Mark Tengler, Michael Sloane, Daniel Lockhart